GALECTIN THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
GALECTIN THERAPEUTICS INC. (GALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 7.50 thousand shares for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-18.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2015-03-18
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2014-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2014-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2013-12-31 was 1.29M shares.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2013-09-30 was 16.67K shares.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2014 was 7.50K shares, a 99.44% decline from fiscal 2013.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2013 was 1.34M shares, a 117.93% increase from fiscal 2012.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2012 was 616.73K shares, a 337.13% increase from fiscal 2011.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2011 was 141.08K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|---|
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-18 | 0.00 shares derived: sum of 2 quarters · filed 2015-03-18 | 7.50K shares 10-K · filed 2015-03-18 | ||
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | 7.50K shares 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | 7.50K shares 10-Q · filed 2014-08-07 | ||||
| 2013-12-31 | 1.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-18 | 1.31M shares derived: sum of 2 quarters · filed 2015-03-18 | 1.34M shares 10-K · filed 2015-03-18 | ||
| 2013-09-30 | 16.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | 50.00K shares 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | 33.33K shares 10-Q · filed 2013-08-14 | ||||
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | 0.00 shares derived: sum of 2 quarters · filed 2014-03-21 | 616.73K shares 10-K · filed 2014-03-21 | ||
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | 616.73K shares 10-Q · filed 2012-11-09 | |||
| 2012-06-30 | 616.73K shares 10-Q · filed 2012-08-10 | ||||
| 2011-12-31 | 141.08K shares 10-K · filed 2013-03-29 | ||||
| 2010-05-31 | 4.50K shares 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |